Abstract

Disclosed in the present application are an isolated anti-IL-17RB antibody or antigen-binding fragment thereof, or a pharmaceutical composition containing same, which are used for treating FLG-associated diseases. The anti-IL-17RB antibody or antigen-binding fragment thereof or the pharmaceutical composition containing same can reverse Th2-driven downregulation of filaggrin expression, and can thus effectively treat FLG-associated diseases.